Jazz Pharmaceuticals (JAZZ) Retained Earnings (2010 - 2026)

Jazz Pharmaceuticals' Retained Earnings history runs 17 years deep, the most recent figure standing at -$651.0 million for Q1 2026.

• On a quarterly basis, Retained Earnings fell 162.91% year-over-year to -$651.0 million in Q1 2026; TTM through Mar 2026 was -$651.0 million, a 162.91% decrease from a year earlier, with the FY2025 full-year figure at -$568.6 million, up 40.0% from the prior year.
• Retained Earnings eased to -$651.0 million in Q1 2026 per JAZZ's latest filing, from -$568.6 million in the prior quarter.
• Across five years, Retained Earnings topped out at $1.0 billion in Q1 2025 and bottomed at -$1.1 billion in Q2 2022.
• The 5-year median for Retained Earnings is -$569.9 million (2025), against an average of -$192.3 million.
• Biggest YoY gain for Retained Earnings was 283.23% in 2022; the steepest drop was 220.43% in 2022.
• Year by year, Retained Earnings stood at $733.6 million in 2022, then climbed by 19.78% to $878.7 million in 2023, then tumbled by 207.85% to -$947.7 million in 2024, then jumped by 40.0% to -$568.6 million in 2025, then fell by 14.49% to -$651.0 million in 2026.
• Per Business Quant, the three latest JAZZ Retained Earnings figures stand at -$651.0 million (Q1 2026), -$568.6 million (Q4 2025), and -$569.9 million (Q3 2025).